“GL-ONC1 and other Genelux vaccinia-based vectors show great promise in the treatment of cancer. The company has also pioneered the development of non-invasive companion imaging capabilities for monitoring the therapeutic efficacy of its viral vectors, and which may aid in the diagnosis and staging of cancer and intra-operative scenarios.
Our leading product candidate, GL-ONC1, incorporates a unique luminescent fluorescent fusion protein, Renilla luciferase- Aequorea Green Fluorescent Protein (GFP) to enable companion optical imaging, This protein is a combination of two proteins from glowing sea pansies and jellyfish. After the virus find and enters a tumor, it begins to replicate, proportionally emittiing light throughout the viral amplication process. In preclinical testing, this has enable accurate, non-invasive detection and optical imaging of cancr progresssion/ regression in real time, as well as microscopic imaging of tumor biopsies at tissue or cellular levels.
Clinical trials of our flaship product GL-ONC1 may utilize this technology to supplement safety and efficacy evaluations. In the future, Genelux therapeutics may contain novel deep tissue imaging capabilities enabling use of PET and MRI scans.”